United States Pharmacopeial Convention (USP). Compounding Compendium. Rockville, MD: USP; 2020.
United States Pharmacopeial Convention (USP). USP general chapter <795> pharmaceutical compounding—nonsterile preparations. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
United States Pharmacopeial Convention (USP). USP general chapter <797> pharmaceutical compounding—sterile preparations. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
United States Pharmacopeial Convention (USP). USP general chapter <800> hazardous drugs—handling in healthcare settings. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
United States Pharmacopeial Convention (USP). USP general chapter <825> radiopharmaceuticals—preparation, compounding, dispensing, and repackaging. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
United States Pharmacopeial Convention (USP). USP general chapter <797> pharmaceutical compounding—sterile preparations. In: USP 42−NF 37. Second Supplement. Rockville, MD: USP; 2019.
Newton DW. United States Pharmacopeia chapter <797> timeline 1989 to 2013. Int J Pharm Compd. 2013; 17:283-8.
US Food and Drug Administration. Repackaging of certain human drug products by pharmacies and outsourcing facilities, 2017. www.fda.gov/downloads/Drugs/Guidances/UCM434174.pdf (accessed 2020 May 22).
Kienle PC. The Chapter <800> Answer Book. Bethesda, MD: ASHP, 2017.
United States Pharmacopeial Convention (USP). USP general chapter <1168> compounding for phase 1 investigational studies. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
US Food and Drug Administration. Compounded drug products that are essentially copies of a commercially available drug product under section 503a of the Federal Food, Drug, and Cosmetic Act, 2018. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf (accessed 2020 May 22).
American Society of Health-System Pharmacists. ASHP sterile products preparation certificate program, 2019. www.ashp.org (accessed 2020 May 22).
CriticalPoint, LLC. Website. www.criticalpoint.info (accessed 2020 May 22).
Board of Pharmacy Specialties. BPS board certified sterile compounding pharmacist (BCSCP). www.bpsweb.org (accessed 2020 May 22).
Pharmacy Technician Certification Board. Certified compounded sterile preparation technician™ program. www.ptcb.org/about-ptcb/news-room/whats-new-at-ptcb/2017/12/06/ptcb-launches-certified-compounded-sterile-preparation-technician-(cspt-)-program (accessed 2020 May 22).
Murdaugh LB. Competence Assessment Tools for Health-System Pharmacies. 5th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2015.
American Society of Health-System Pharmacists (ASHP). ASHP’s Pharmacy Competency Assessment Center. Bethesda, MD: ASHP; 2019.
United States Department of Labor, Occupational Safety and Health Administration. Hazard communication. www.osha.gov/dsg/hazcom/HCSFinalRegTxt.html (accessed 2020 May 22).
Centers for Disease and Control Prevention. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. Publication number 2016-161. www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf (accessed 2020 May 22).
United States Department of Labor, Occupational Safety and Health Administration. Hazard communication: small entity compliance guide for employers that use hazardous chemicals. www.osha.gov/Publications/OSHA3695.pdf (accessed 2020 May 22).
Centers for Disease Control and Prevention. Hand hygiene in healthcare settings. www.cdc.gov/handhygiene (accessed 2020 May 22).
ASTM International. ASTM D6978 standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs. www.astm.org/Standards/D6978.htm (accessed 2020 May 22).
ASTM F739-12e1. Standard Test Method for Permeation of Liquids and Gases through Protective Clothing Materials under Conditions of Continuous Contact. West Conshohocken, PA: ASTM International.
Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. The national personal protective technology laboratory, respirator trusted-source information. www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource.html (accessed 2020 May 22).
Centers for Disease Control and Prevention. Safe injection practices to prevent transmission of infections to patients. www.cdc.gov/injectionsafety/ip07_standardprecaution.html (accessed 2020 May 22).
Association for Professionals in Infection Control and Epidemiology. APIC position paper: safe injection, infusion, and medication vial practices in health care (2016). www.apic.org/Resource_/TinyMceFileManager/Position_Statements/2016APICSIPPositionPaper.pdf (accessed 2020 May 22).
Buchanan C, Schneider P, Forrey R. Compounding Sterile Preparations. 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
United States Pharmacopeial Convention (USP) general chapter <71> sterility tests. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
US Food and Drug Administration. FD&C Act provisions that apply to human drug compounding. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm606955.htm (accessed 2020 May 22).
United States Pharmacopeial Convention (USP). USP general chapter <1231> water for pharmaceutical purposes. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
Controlled Environment Testing Association. CETA application guides. www.cetainternational.org (accessed 2020 May 22).
Institute for Safe Medication Practices. Guidelines for safe preparation of compounded sterile preparations. www.ismp.org/guidelines/sterile-compounding (accessed 2020 May 22).
United States Pharmacopeial Convention (USP). USP general chapter <659> packaging and storage requirements. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
Rhoads R, Exner L, Wagner JT. Demystifying dynamic smoke pattern tests for sterile compounding pharmacies. Am J Health-Syst Pharm. 2020;77:56-60.
US Food and Drug Administration. Bulk drug substances used in compounding under section 503a of the FD&C Act. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm614204.htm (accessed 2020 May 22).
US Food and Drug Administration. Regulatory policy information. www.fda.gov/drugs/human-drug-compounding/regulatory-policy-information (accessed 2020 May 22).
United States Pharmacopeial Convention (USP). USP general chapter <1178> good repackaging practices. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
American Society of Health-System Pharmacists. ASHP guidelines on compounding sterile preparations. Am J Health-Syst Pharm. 2014; 71:145-66.
Power LA, Coyne JW. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2018; 75:1996-2031.
Centers for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories (BMBL). 5th ed. www.cdc.gov/labs/BMBL.html (accessed 2020 May 22).
International Journal of Pharmaceutical Compounding. Website. www.ijpc.com (accessed 2020 May 22).
Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. www.cdc.gov/mmwr/preview/mmwrhtml/mm5132a9.htm (accessed 2020 May 22).
American Society of Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 20th ed. Bethesda, MD: ASHP; 2018.
Dellamorte Bing C, Nowobilski-Vasilios A. Extended Stability for Parenteral Drugs. 6th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
King Guide Publications, Inc. King Guide to Parenteral Admixtures. Napa, CA: King Guide Publications; 2019.
US Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (accessed 2020 May 22).
United States Pharmacopeial Convention (USP). USP general chapter <1113> microbial characterization, identification, and strain typing. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
United States Pharmacopeial Convention (USP). USP general chapter <1163> quality assurance in pharmaceutical compounding. In: USP 43−NF 38 as of June 1, 2020. Rockville, MD: USP; 2020.
US Food and Drug Administration. Insanitary conditions at compounding facilities. www.fda.gov/media/124948/download (accessed 2020 May 22).
accreditation organizations, 1
action levels, 6
for air sampling, 127–128
gloved fingertip and thumb test and, 44
in sampling plan, 124
for surface sampling, 129, 130–131
action plan, 135–136
active air sampling, 121, 123, 124, 126–128
active pharmaceutical ingredients (APIs)
beyond-use dates (BUDs) of, 106
compounding, 89
eye and respiratory risk when working with, 23
use of, 52–53
addEASE®, 89, 106
ADD-Vantage™, 89, 106
administration of medications
compounding distinguished from, 10–12
policies concerning, 33
preparation for, 33–34
air changes per hour (ACPH)
for air handing system, 69
calculating, 64
for chemo room, 63
for cleanroom suite, 69
for containment segregated compounding area, 71
facility requirements for, 55, 58–59
for IV room, 62
for segregated compounding area, 59
for storage room, 60
air flow
dwell time and, 114
dynamic air flow testing of PEC, 80
environmental monitoring and, 123
in pass-through chambers, 68, 73, 74
training and, 37
air handling system, 58, 62, 81, 131
albumin, 91–92
alcohol as disinfectant/sanitizing agent, 114, 120
alcohol-based hand gel, 24
alert level, 124
algorithm, 89–90
allergenic extracts, 6
compounding area, 76–77
compounding process, 95
immediate use and, 36
allergenic extracts compounding area (AECA), 76–77
allergens, 4
amber dropper bottles, 91
American Chemical Society (ACS) marking, 53
anesthesia personnel, 36
animals, application of USP <797> to, 9
anterooms, 21, 64–67
active air sampling in, 127
air changes per hour (ACPH) in, 58
cleaning, 64, 121
in cleanroom suite, 62, 68–69, 70, 71
dirty side distinguished between clean side, 64
facility requirements for, 55, 56
garb and, 24, 26–27, 30
gloved fingertip and thumb test in, 43, 44
line of demarcation in, 64, 66
mold in, 131
office space in, cleaning, 121
pass-through chambers to, 72
pressure in, 62, 63, 68, 79, 81
antibiotics
beyond-use-dates, 104
master formulation record for, 93
saline bag used for reconstituting, 107
syringes, reconstituted and frozen, 104
vials, reconstitution of, 34
appendices, USP <797>, 7
Aseptic Compounding Technique: Learning and Mastering the Ritual, 39
aseptic technique, 5, 6, 46
beyond-use dates (BUDs) and, 99, 101
competency in, 15, 37
immediate use preparations and, 11
insanitary conditions and, 134
training in, 46
ASHP Guidelines on Compounding Sterile Preparations and Guidelines on Handling Hazardous Drugs, 89
ASTM F739-12e1 (Standard Test Method for Permeation of Liquids and Gases through Protective Clothing Materials under Conditions of Continuous Contact), 26
ASTM Standard D6978, the Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs, 25–26
autoclaves, 37, 91, 99
autologous serum, 91
automated compounding device (ACD)
cleaning, 120
sampling, 128
testing, 82
availability of USP <797>, 1–2
bacterial contamination, 81, 123, 125, 127
Banana Bag, 35
Basics of Aseptic Compounding Technique Videos and Training, 39
beyond-use dates (BUDs), 5, 7, 22, 99–109
4-hour allowance and, 35
for active pharmaceutical ingredients and other components, 106
anteroom and, 66–67
biologics, 91–92
of chemos, 100
for compounded stock bags, 108–109
compounding aseptic isolators and, 61
designated person for monitoring, 14
expiration date differentiated from, 99
general information on, 99–105
for high-risk preparations, 102, 103, 105
immediate use and, 33
infusion time differentiated from, 99
in-use time differentiated from, 99
for low-risk preparations, 100, 102, 103, 105
in master formulation record (MFRs), 97, 98
maximum, 100, 102–103
for medium-risk preparations, 100, 103, 105
reconstituting systems and, 89
sterility testing and, 91
for vial/bag systems, 106
for vials and other dosage forms, 106–108
biological safety cabinet (BSC), 5, 21, 29, 57, 58, 60, 77
biologics, 91–92
biomechanical engineering, 74, 82
Biosafety in Microbiological and Biomedical Laboratories (BMBL) document, 91
bleach, 117–118
blood components, 91
Board of Pharmacy Specialties (BPS), 14, 39
Certified Sterile Compounding Pharmacist (BCSCP) certification, 39
bubble point test, 91
buffer rooms
active air sampling in, 127
air changes per hour (ACPH) in, 55, 58, 71
anterooms and, 64, 65, 66–67
cleaning and disinfecting, 115, 118, 121
cleanroom suites and, 68, 69
containment segregated compounding areas and, 71
dynamic conditions in, 84
engineering controls for, 60–61, 62, 63, 64
facility requirements for, 55, 56, 57
garbing and, 26–27, 30
mold in, 132
monitoring, 79, 81
negative pressure, 26–27, 58, 60–61, 63, 70, 71, 73, 79, 81, 132
pass-through chambers and, 72
policies required and recommended in USP <797>, 21
positive pressure, 30, 58, 62, 68, 79, 81
presterilization procedures and, 67
refrigerators or freezers in, 73
segregated compounding areas and, 70
bulk drug substances, 52, 88
calculations, 15, 37, 94
calibration, 48, 58, 75, 79, 83, 125
cameras, 61
cardboard, 59
cefazolin syringes, 91
cellphones, 87
Centers for Disease Control and Prevention (CDC)
Biosafety in Microbiological and Biomedical Laboratories (BMBL) document, 91
hand hygiene defined by, 24
Safe Injection Practices, 33
Certificate of Analysis (CoA), 48, 53, 88, 90
certification and recertification, 80, 83–86, 123
Certification Application Guides (CAGs), 80, 83, 86
certification reports, 59
Certified Compounded Sterile Preparation Technician™ (CSPT™), 14, 40
Chapter <800> Answer Book, The, 3, 20, 23, 39, 55, 57, 61, 69, 122
chemo
beyond-use dates (BUDs) for, 100
gloves, 25–26
gowns, 26–27
rooms, 63, 65, 69, 70, 85, 113
classified devices or rooms, 55–56
cleaning and disinfecting, 6, 113–122
cleaning solutions for, 117–118
compounding areas, 120–122
core competencies in, 37
general information, 113–117
PECs and other compounding equipment, 118–120
policies required and recommended in USP <797>, 22
respiratory protection for, 29
supplies needed for compounding, 122
cleanroom suites, 67–69, 70
beyond-use dates (BUDs) and, 100
engineering controls, 61–64, 67–69, 70
pass-through chambers to, 71–73
clean side of anteroom, 64
clerkship students, 40
closed system drug-transfer devices, 37
Code of Federal Regulations (CFR), 88
colony-forming units (CFUs), 43, 44–45, 124, 126, 131, 132
commissioning, 124
community pharmacies, 10
competence, documenting, 15–16
Competence Assessment Tools for Health-System Pharmacies, 15
competencies
of compounding personnel, 15, 37–40
documentation of, 16, 38
hand hygiene, 117
initial training and, 37–40
retraining and, 49
compliance with USP <797>, 3, 9, 11
components
of allergen extracts, 77
aseptic technique and, 46
beyond-use-dates (BUDs) and, 99, 100, 103, 104, 106
blood, 91
cleaning, 119, 120, 122
compounded sterile preparations, 51–52
core competencies in moving, 37
of immediate-use preparations, 33, 35
labeling, 111–112
manufactured products as, 51
media fill test and, 47
nonsterile starting, 52–53
in nonsterile-to-sterile compounding, 90–92
of pass-through chambers, 71
policies required and recommended in USP <797>, 20, 21
of quality assurance program, 133
of required garb, 23, 24, 29–30
storage of, 57–58, 60
Compounded Drug Products That Are Essentially Copies of Commercially Available Drug Products under Section 503A of the Federal Food, Drug, and Cosmetic Act, 11
compounded sterile preparations (CSPs)
antibiotics, 34, 93, 104, 107
facility requirements for, 55
immediate-use (see immediate-use CSPs)
initial training to mix, 37
intrathecal or epidural, 88, 105
labeling, 111–112
for long-term care facilities, 10
maintaining sterility, purity, and stability of, 7
presterilization areas for weighing powders, 67
risk levels, 5, 6, 49, 51–52, 100, 102, 127
segregated compounding areas for nonhazardous, 69–70
Compounded Sterile Preparations Pharmacist (BCSCP), 14
compounded stock bags, 109–110
compounding
activities not considered as, 10
administering medications distinguished from, 11–12
algorithm for determining appropriateness of, 89–90
allergenic extracts, 6, 36, 76–77, 95
with blood components, 91
cleaning supplies needed for, 122
compounding records, 94–95, 98
general information, 87–90
of immediate-use CSPs in ambient air, 75–76
master formulation records (MFRs), 14, 21, 92–93, 97
nonsterile-to-sterile, 90–92
personnel (see compounding personnel)
policies required and recommended in USP <797>, 21
radiopharmaceuticals, 95–96
compounding areas
allergenic extracts, 76–77
cellphones in, 87
cleaning of, 120–122
designation of, 21
facilities design for, 55–59
maximum number of personnel in, 87
monitoring of, 20
order of donning garb for, 30
other equipment in, 74–75
policies required and recommended in USP <797>, 20–21
segregated radiopharmaceutical processing areas, 77–78
temperature and humidity requirements for, 57–58
compounding aseptic containment isolators (CACIs), 58
compounding aseptic isolators (CAIs), 24, 25, 43, 47, 58, 61, 67, 68
compounding personnel
responsibilities of, 15, 21
students as, 87
training of, 15–16, 20, 37–41
compounding records (CRs), 94–95, 98
Compounding Sterile Preparations, 39
Compounding Sterile Preparations: ASHP’s Video Guide to Chapter <797>, 39
computer equipment
cleaning, 120
tablets, 75
contact lenses, 28
contact plates, 130
containers, sterile, 91
containment segregated compounding areas (C-SCAs), 56, 70–71, 129
containment ventilated enclosure (CVE), 67
contents of sections of USP <797>, 5–7
Controlled Environment Testing Association (CETA), 21, 59, 60, 72, 80, 83, 86
conventionally manufactured products, 51–52, 78, 80, 92, 108
CriticalPoint, LLC, 14, 38
cross-contamination, 91, 134
daily nonviable monitoring, 79–82
deactivating, 113
decontaminating, 113
dehumidifiers, 81
depyrogenation. see sterilization and depyrogenation
designated person, 13–14, 20
dirty side of anteroom, 64
disinfecting. see cleaning and disinfecting
dispensing, 10, 111–112
disposable garb, 24
DNV-GL Healthcare, 1
documentation
certification reports, 59
of competence, 16, 38
of training, 38, 40
doffing of PPE, 24
donning of PPE, 24, 30
doors
in allergenic extracts compounding area, 77
cleaning, 116
in pass-through cleanroom, 71
placement of, 63
pressure and, 81
refrigerator, 73, 74
in segregated compounding areas, 69–70
in segregated radiopharmaceutical processing area, 78
dropper bottles, 91
dry anterooms, 66
dwell time, 113, 114, 116, 117, 120
dynamic conditions, 84
earrings, 27
electrolyte bags, 108–109
engineering controls, 60–64
primary, 60–61
secondary, 62–64
environmental monitoring, 123–130
active air sampling, 126–128
general information, 123–126
out-of-specification results, 131–132
surface sampling, 128–130
Environmental Protection Agency (EPA), 113–117, 120, 122
epidural CSPs, 88, 105
equipment and supplies
calibration of, 48, 58, 75, 79, 83, 125
cleaning, 118–120
computers, 75, 120
core competencies in using, 37
incubators (see incubation)
other compounding area, 74–75
printers, 64, 74
records of, 21
refrigerator and freezer (see freezers; refrigerators)
storage of, 59–60
warmers, 48, 75, 79, 104, 125
expiration date
1-year expiry date, 53
of active pharmaceutical ingredients, 106
beyond-use date (BUDs) differentiated from, 99
of chemicals marked USP or NF, 53
in compounding record, 94, 98
of a manufactured solution, 107
Extended Stability for Parenteral Drugs, 39, 105
eyeglasses, 28
eye protection, 28–29, 113
eyewash stations, 21, 63
face shields, 28
facility design
allergenic extracts in compounding area, 76–77
anterooms, 64–67
cleanroom suites, 68–69
compounding immediate-use CSPs in ambient air, 75–76
containment segregated compounding areas for hazardous CSPs, 70–71
general information on, 55–59
other compounding equipment, 74–75
pass-through chambers, 71–73
presterilization area for weighing powders, 67
refrigerator and freezer placement, 73–74
segregated compounding areas for nonhazardous CSPs, 69–70
segregated radiopharmaceutical processing area, 77–78
storage areas, 59–60
filtration, 67, 91, 99, 101
Food and Drug Administration (FDA), 1
503A pharmacies, 11, 51, 52, 88
503B outsourcing facilities, 51, 88, 89, 109
approved labeling, 33–34
beyond-use dates (BUDs) and, 106
on bulk drug substances, 52, 88
Compounded Drug Products That Are Essentially Copies of Commercially Available Drug Products, 11
on drugs that should not be compounded, 88
Insanitary Conditions at Compounding Facilities, 134
List of Drug Products That Have Been Withdrawn or Removed from the Market for Reasons of Safety or Effectiveness, 88
repackaging and, documents on, 3, 89
four hour beyond-use date, 35
freezers
beyond-use dates (BUDs) and, 100, 103–104
placement of, 73–74
temperatures in, 21, 79, 99, 102
fungal contamination, 47, 81, 123, 125, 127
garbing, 23–31
for cleaning, 113
core competencies in, 37
eye protection, 28–29, 113
general information on, 23–24
gloves, 20, 25–26
gowns, 20, 26–27
hair/head covers, 20, 27, 30
masks, 20, 27–28, 29
policies required and recommended in USP <797>, 20
procedures, 29–31
shoe covers, 20, 28
storage, 57
training in, 42
General Chapters, 1
General Notices, 1
general principles of USP <797>, 3–4
Getting Started in Aseptic Compounding, 39
Glossary, USP <797>, 7
gloved fingertip and thumb test
clerkship students and, 40
competency and, 37
environmental services personnel and, 116–117
immediate-use CSPs and, 36
for personnel who mix only immediate-use CSPs, 48
requalification, 49
training, 15–16, 40, 87
gloves, 20, 25–26
goggles, 24, 28, 113
gowns, 20, 26–27
Guidelines for Safe Preparation of Compounded Sterile Preparations (ISMP), 61
Guide to Parenteral Admixtures, 105
hair/head covers, 20, 27, 30
Handbook of Injectable Drugs, 105
hand hygiene, 24–25
competency in, 37, 41
documenting, 41
Hand Hygiene in Healthcare Settings (CDC), 41
meaning of, 24
policies required and recommended in USP <797>, 20
hazard communication plan, 16–17
hazardous drugs (HDs), 3, 5, 9, 10
chemo gloves for handling, 25–26
cleaning supplies for, 122
containment segregated compounding areas for, 70–71
decontamination for, 113
garb for, 23
hazard communication plan for, 16–17
minimum facility requirements for, 55
Hazardous Drugs—Handling in Healthcare Settings: ASHP’s Guide to USP Chapter <800>, 39
high efficiency particulate air (HEPA) filters
active air sampling and, 127
air changes per hour (ACPH) and, 58
certifier and, 80, 83, 84
cleaning agents applied to, 118
in cleanroom suites, 68, 69, 70, 71
out-of-specification results and, 132
in pass-through chambers, 71–72
secondary engineering controls and, 62
surface sampling and, 129
highly pathogenic organisms, 124
high-risk preparations
bacterial and fungal contamination of, 125, 127
beyond-use dates (BUDs) for, 102, 103, 105
mixing, 15–16, 43, 46, 49
overview of, 52
high-touch areas, 121
hoods
allergenic extracts compounding area and, 77
beyond-use dates (BUDs) and, 108
certification of, 84–86
cleaning, 118–119, 120, 121
computer tablet in, 75
engineering controls and, 60, 61, 63
facility requirements for, 55, 56, 57
in nuclear medicine department, 78
out-of-specification results and, 132
perimeter around, 70
testing before using, 124
hospital pharmacies, 10
human resources, 13–17
compounding personnel, responsibilities of, 15
designated person, 13–14
documenting competence, 15–16
hazard communication plan, 16–17
humidifiers, 58, 81
humidity requirements and monitoring
dehumidifiers, 81
documenting, 79
gauges, 59
humidifiers for, 58, 81
for IV room, 62, 64
for sterile compounding area, 57–58, 81
immediate use, defined, 33
immediate-use CSPs, 33–36
4-hour allowance and, 35
compounding, in ambient air, 75–76
mixing, 34, 87
time limit for using, 11, 35
incubation, 125–126
length of, 127
media fill test and, 47, 48
methods of, 43, 125
by microbiology laboratory, 125
by outside laboratory, 125
in pharmacy, 125, 126
in sterile compounding area, 75
temperature, 42, 79, 124, 125, 127, 129
Infection Control Committee meeting, 133–134
infusion time, 99, 102
beyond-use date (BUDs) differentiated from, 99
organizational policy on, 102
initial training, 37–41
insanitary conditions, 134
Insanitary Conditions at Compounding Facilities (FDA), 134
Institute for Safe Medication Practices (ISMP), 61
International Journal of Pharmaceutical Compounding, 93
International Organization for Standardization (ISO) standards
for active air sampling, 127–128
for air changes per hour (ACPH), 58
ambient air and, 75, 76
for anterooms, 64, 65, 66–67, 131
beyond-use-dates (BUDs) and, 107, 108, 109
for cleanrooms, 55–56, 68
for containment segregated compounding areas, 71
for HEPA-filtered pass-throughs, 72
for hoods, 60
for incubation, 125
for nuclear medicine departments, 78
for presterilization procedures, 67
for segregated compounding areas, 70
for surface sampling, 128, 129, 130, 131
intrathecal CSPs, 88, 105
intravenous immunoglobulin (IVIG), 91–92
in-use time, beyond-use date (BUDs) differentiated from, 99
investigational agents, 10
irrigation, 9
bottles, 107
sterile water for, 53, 118
IV bags
beyond-use dates (BUDs) of, 107
cleaning, 121
IV hoods, 35
IV rooms
ceiling HEPA filters in, 84
cleaning and disinfecting, 115, 116
for office-related space, 56
pass-through chambers and, 72
temperature of storage areas outside, 80
IV software systems, 85
IV solutions, immediate-use, 35
The Joint Commission, 1
labeling, 22, 33–34, 111–112
Lactated Ringers, 36
laminar airflow workbenches (LAFWs), 58, 68
lidocaine preparations, 36
line of demarcation in anterooms, 64, 66
long-term care (LTC) facilities, 10
lot numbers, 48, 94, 95, 111, 122
low-linting disposable towels/wipers, 25, 118
low-linting gowns, 26
low-risk preparations
bacterial and fungal contamination and, 125
beyond-use dates (BUDs) for, 100, 102, 103, 105
overview of, 51, 52
mail-order pharmacies, 10
malt extract agar, 127
mannitol warmer, 48, 125
marking
American Chemical Society, 53
in anteroom, 64
beyond-use dates (BUDs), 106
in nonsterile-to-sterile compounding, 90
in surface sampling, 130
USP or NF, 52, 53
masks, 20, 27–28, 29
master formulation records (MFRs), 14, 21, 92–93, 97
material safety data sheets (MSDSs), 16–17
measuring and mixing, 37
media fill test
aseptic technique and, 46
clerkship students and, 40
competency and, 37
gloved fingertip and thumb test and, 43, 45
immediate-use CSPs and, 36
for personnel who mix only immediate-use CSPs, 48
requalification, 49
training, 15–16, 40, 46–49, 87
medications, administration of. see administration of medications
medium-risk preparations
bacterial and fungal contamination and, 125
beyond-use dates (BUDs) for, 100, 103, 105
mixing, 15–16, 43, 46, 49
overview of, 52
meningitis scare of 2012, 1
microbial contamination risk levels, 5
microbiology departments, 125–126
MINI-BAG Plus, 89, 106
mold, 131–132
monitoring, daily nonviable, 79–82
monographs, 1, 52, 88, 93, 99, 101, 104
monthly cleaning, 116
mops, reusable, 114
music, 87
N95 respirators, 29
National Formulary (NF) marking, 53
National Institute for Occupational Safety and Health (NIOSH), 16, 26, 29, 33, 57, 60–61, 63, 70, 73, 122
needles, cleaning of, 122
negative pressure buffer rooms, 26–27, 58, 60–61, 63, 70, 71, 73, 79, 81, 132
neonatal total parenteral nutrition (TPN), 108–109
nonhazardous CSPs
cleaning supplies for, 122
segregated compounding areas for, 69–70
nonsterile preparations, 1, 9, 10, 11, 86, 95–96
nonsterile starting components, 52–53
nonsterile-to-sterile compounding, 90–92
nonviable monitoring, 79–82
nuclear medicine departments, 78
nuclear medicine technologists, 45, 49
Nuclear Regulatory Commission (NRC), 95–96
nursing homes, 10
Occupational Safety and Health Administration (OSHA), 16–17
one off compounding, 94
one-step disinfectant cleaner, EPA-registered, 113, 114, 115, 116, 117, 120, 122
operating room (OR)
beyond-use dates (BUDs) and prepping for, 107
OR greens for, 24
out-of-specification results, 131–132
outsourcing facilities
bulk list for, 88
premixed solutions from, 89
stock bags from, 110
packaging, 22, 111–112
paddles for surface sampling, 129
paper towels, 25, 118
pass-through chambers, 71–73
air sampling in, 127
cleaning of, 121
personal hygiene, 5, 20, 24–25, 37
personal protective equipment (PPE), 23, 24, 29. See also garbing
personnel training. See training
pharmaceutical manufacturers
compliance of, 10
expiration dates, 52–53
lot numbers, 94
premixed solutions from, 89
vial tops from, 88
pharmacy bulk package (PBP), 108
Pharmacy Competency Assessment Center, ASHP, 15
Pharmacy Compounding Accreditation Boards, 1
Pharmacy Technician Certification Board (PTCB), 14, 39–40
physician offices, 10, 13
plastic curtains/drapes, 56
platelet, 91
policies and procedures, 19–22
positive pressure buffer rooms, 30, 58, 62, 68, 72, 79, 81
powder hoods, 86
powders
garb for compounding, 23, 31
presterilization area for weighing, 67
powered air purifying respirators (PAPRs), 29
power loss, 120
premixed solutions, 89
prepackaging, 11, 89
preparation for administration, 33–34
pressure requirements and monitoring
in anterooms, 62, 63, 68, 79, 81
in negative pressure buffer rooms, 26–27, 58, 60–61, 63, 70, 71, 73, 79, 81, 132
in positive pressure buffer rooms, 30, 58, 62, 68, 72, 79, 81
presterilization area for weighing powders, 67
presterilization areas, 67
primary engineering controls (PEC), 60–61
certification, 123
cleaning and disinfecting of, 115, 118–120
surface sampling, 128–129
printers, 64, 74
probability of a nonsterile unit (PNSU), 91
proprietary bag systems, 7, 89
quality assurance and quality control, 6, 22, 133–134
radiopharmaceuticals, 1, 5, 135
addressed in 797, 3
compounding, 95–96
immediate use of, 45, 49
segregated processing area for, 77–78
UltraTag™, 92
recertification, 84–85
reconstitution, 34, 104
red cells, 91
refrigerators
beyond-use dates (BUDs) and, 100, 103–104, 108–109, 132
cleaning of, 121
low wall return for, 74
pass-through, 73, 74
placement of, 73–74
in sterile compounding area, 64
surface sampling and, 128
temperatures in, 21, 79, 99, 102
release preparation release checks and tests, 7, 21
religious head coverings, 27
repackaging, 3, 11
repeater pumps, 74, 79, 82, 84, 120, 128
requalification, 49
respirators, 27, 28, 29
restricted access barrier system (RABS), 68
reusable garb, 24
reusable mops, 114
risk levels, 5, 6, 49, 51–52, 100, 102, 127
robots, 61
RODAC™, 130
Safe Injection Practices (CDC), 33
safety data sheets (SDSs), 16–17
sampling plan, 124
sanitizing. See cleaning and disinfecting
scales, 61
scope of USP <797>, 9–11
secondary engineering controls (SEC), 62–64, 123
segregated compounding areas (SCA)
air changes per hour (ACPH) in, 59
allergen extracts preparation in, 76
anterooms for, 65, 66–67
beyond-use dates (BUDs) and, 100
cardboard in, 59
cleaning and disinfecting of, 115
facility design and, 56, 57
garb in, 24, 26, 30
gloved fingertip and thumb test done in, 43, 44
for nonhazardous CSPs, 69–70
restrictions, 40–41
as secondary engineering control, 62, 63
surface sampling and, 129
segregated radiopharmaceutical processing area (SRPA), 77–78
settling plates, 127
shelving, 21, 59, 63, 64, 66, 116
shipping boxes, 59
shoe covers, 20, 28
single-dose ampules, 107
single-dose vials, 107
sinks
in allergenic extracts compounding area, 77
in anteroom, 64, 66, 131
in cleanroom suite, 69
in containment segregated compounding areas, 71
facility design and, 57, 62
garbing and, 23, 29–31, 64
in segregated compounding areas, 70
in segregated radiopharmaceutical processing area, 78
sleeve covers, 28
Small Entity Compliance Guide for Employers That Use Hazardous Chemicals, 17
sodium bicarbonate IV, 11, 34–35
soybean-casein digest media, 47, 127
spills, 15, 20, 29, 119, 120
sporicidal agents, 115, 116, 122
bleach as, 117–118
for cleaning hoods after power outage, 120
for mold, 132
reason for using, 113
rotating, 114
sprinkler heads, 63
stability, 11, 92, 97, 99, 100, 101, 104, 105, 106, 108
standard operating procedures (SOPs), 6, 19–22
sterile containers, 34–35
sterile products and preparations. see USP <797> Pharmaceutical Compounding—Sterile Preparations
Sterile Products Preparation Certificate Program, ASHP, 14
sterilization and depyrogenation, 6
storage areas
in anterooms, 66
facility design and, 59–60
for garb, 57
policies required and recommended in USP <797>, 21
segregated compounding areas used as, 64
temperature in, 79
supplies. see equipment and supplies
surface sampling, 128–130
surfaces and finishes, 59, 62, 63, 67
syringes
cefazolin, 91
cleaning, 122
containers, 89
immediate-use provisions, 36
reconstituted and frozen, 104
sterility tests and, 91
tape, for separating anteroom, 67
technician certification, 39–40
temperature requirements and monitoring
beyond-use-dates (BUDs) and, 102
gauges for, 59
for incubators, 129
monitoring, 79, 80
secondary engineering controls, 62, 64
for shipped products, 112
for sterile compounding area, 57–58
terminal cleaning, 119
terminal sterilization, 91
TNTC (too numerous to count), 126
total parenteral nutrition (TPN), 52, 108
touchscreen monitors, 61
training, 37–49
aseptic technique, 46
for compounding personnel, 15–16, 20, 37–41
for designated person, 14
documented, 38
evaluation, 5
garbing, 42
gloved fingertip and thumb test, 42–45
hand hygiene, 41
initial, 37–41
media fill test, 15–16, 46–49
requalification, 49
trypticase soy agar (TSA), 42, 127, 129
UltraTag™, 92
United States Pharmacopeia (USP) marking, 52
United States Pharmacopeial Convention, 1United States Pharmacopeia–National Formulary (USP–NF), 52, 53, 88, 101
USP <71> Sterility Tests, 47
USP <659> Packaging and Storage Requirements, 80, 102
USP <795> Pharmaceutical Compounding—Nonsterile Preparations, 1, 9, 10, 11, 86, 95–96
USP <797> Pharmaceutical Compounding—Sterile Preparations, 1
administration, immediate use and preparation for, 33–36
allergens, 4
applied animals, 9
availability of, 1–2
beyond-use dates (BUDs), 5, 7, 14, 22, 33, 61, 67, 89, 91, 98, 99–109, 111
certification of engineering controls, 83–86
cleaning and disinfecting, 113–122
compounding, 87–98
contents of sections of, 5–7
daily nonviable monitoring, 79–82
dispensing and packaging, 111–112
enforcement of, 11
environmental monitoring, 123–132
examples of preparations that must comply, 9
facility design, engineering controls, and equipment, 55–78
full text of, where to find, 1
garb and hand hygiene, 6, 23–31
general information, 51
general principles of, 3–4
as a guideline versus a requirement, 1
hazardous drugs addressed in, 3
human resources, 13–17
initial training for compounding, 37–41
mixed by nurses for immediate use, 34
must and should in, distinction between, 3
need for, meningitis scare of 2012 and, 1
nonsterile-to-sterile compounding of, 90–92
personnel training and competence documentation, 37–49
policies and procedures, 19–22
quality assurance and quality control, 6, 22, 133–134
receiving areas for, 57
revision to, in 2019, 3
scope of, 9–11
as a standard, 1–2, 9
sterile products and supplies, 51–53
where to start with information from, 135–136
see also compounded sterile preparations (CSPs)
USP <800> Course, 39
USP <800> Hazardous Drugs—Handling in Healthcare Settings, 1, 3, 39
USP <825> Radiopharmaceutical—Preparation, Compounding, Dispensing, and Repackaging, 1, 3, 45, 49, 77–78, 92, 95–96, 135
USP <1113> Microbial Characterization, Identification, and Strain Typing, 126
USP <1163> Quality Assurance in Pharmaceutical Compounding, 133
USP <1168> Compounding for Phase 1 Investigational Studies, 10
USP <1178> Good Repackaging Practices, 89
USP Compounding Compendium, 1, 93, 101
USP monographs, 1
active pharmaceutical ingredient and, 52
beyond-use dates (BUDs) and, 99, 101, 104
drugs that should not be compounded and, 88
in master formulation record (MFRs), 97
where to find, 93, 101
vaccines, 91–92
veterinary clinics, 13
viable monitoring, 79, 123
vial bag systems, 7, 89
VIAL-MATE, 89, 106
vials
beyond-use dates (BUDs) of, 108
cleaning of, 122
tops of, 88, 108
warmers, 48, 75, 79, 104, 125
washable gowns, 26
waste segregation and disposal, 22
water as component, 53
weekly cleaning, 116
weighing rooms, 67
wet anterooms, 66
white cells, 91
windows in pass-through chambers, 72
wipers, 25, 118